Table 5. Associations between nuclear ERα and immune markers.
| Variable | (A) All patients | (B) Patients with pT1a disease | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Nuclear ERα, N (%) | P | Nuclear ERα, N (%) | P | |||||||
| Negative | Positive | Negative | Positive | |||||||
| Tumoral CD3 | 0.012 | 0.07 | ||||||||
| Low | 425 | (86) | 72 | (14) | 179 | (84) | 34 | (16) | ||
| High | 314 | (79) | 84 | (21) | 149 | (76) | 46 | (24) | ||
| Stromal CD3 | 0.043 | <0.001 | ||||||||
| Low | 501 | (85) | 89 | (15) | 235 | (86) | 39 | (14) | ||
| High | 224 | (79) | 59 | (21) | 87 | (70) | 37 | (30) | ||
| Tumoral FoxP3 | <0.001 | <0.001 | ||||||||
| Low | 391 | (91) | 38 | (9) | 168 | (92) | 15 | (8) | ||
| High | 341 | (75) | 116 | (25) | 155 | (71) | 63 | (29) | ||
| Stromal FoxP3 | 0.027 | 0.028 | ||||||||
| Low | 471 | (85) | 85 | (15) | 223 | (84) | 44 | (16) | ||
| High | 241 | (79) | 66 | (21) | 98 | (74) | 35 | (26) | ||
| Tumoral FoxP3/CD3 index | <0.001 | <0.001 | ||||||||
| Low | 457 | (89) | 56 | (11) | 196 | (88) | 26 | (12) | ||
| High | 273 | (74) | 98 | (26) | 127 | (71) | 52 | (29) | ||
| Stromal FoxP3/CD3 index | 0.006 | 0.07 | ||||||||
| Low | 526 | (85) | 92 | (15) | 236 | (83) | 48 | (17) | ||
| High | 175 | (77) | 53 | (23) | 78 | (74) | 27 | (26) | ||
| IL-7 R | 0.41 | 0.022 | ||||||||
| Low | 440 | (84) | 85 | (16) | 228 | (84) | 44 | (16) | ||
| High | 299 | (81) | 68 | (19) | 98 | (74) | 35 | (26) | ||
| IL-12Rβ2 | 0.96 | 0.96 | ||||||||
| Low | 557 | (83) | 117 | (17) | 238 | (80) | 60 | (20) | ||
| High | 180 | (82) | 39 | (18) | 88 | (81) | 21 | (19) | ||
Significant P-values (<0.05) are shown in bold.
ER, estrogen receptor; FoxP3, forkhead box P3; IL-7R, interleukin-7 receptor; IL-12Rβ2, interleukin-12 receptor β2